Administration of HES, dextrane solutions or > 500 ml of Gelatin solutions within the 24 h prior to randomization
Death expected within the next 48 h (moribund patients as defined by ASA = class V)
Patients whose medical condition does preclude the PLR manoeuvre
Patients for whom the need of pressure infusions are expected
Requirement for renal support (either continuous or discontinuous techniques, including intermittent haemodialysis, haemofiltration and haemodiafiltration)
Patients receiving therapeutic heparin medication due to chronic coagulation disease / anticoagulation medication (i.e. partial thromboplastin time > 60 sec)
Acutely burned patients
Contraindications according to summary of product characteristics of investigational test and reference product
Simultaneous participation in another interventional clinical trial (drugs or medical devices studies)

NCT02715466_exc_T1
Drug
HES
NCT02715466_exc_T2
Drug
dextrane solutions
NCT02715466_exc_T3
Multiplier
> 500 ml
NCT02715466_exc_T4
Drug
Gelatin solutions
NCT02715466_exc_T5
Temporal
within the 24 h prior to randomization
NCT02715466_exc_T6
Scope
HES, dextrane solutions or > 500 ml of Gelatin solutions
NCT02715466_exc_T7
Observation
Death expected
NCT02715466_exc_T8
Temporal
within the next 48 h
NCT02715466_exc_T9
Condition
moribund
NCT02715466_exc_T10
Measurement
ASA
NCT02715466_exc_T11
Value
= class V
NCT02715466_exc_T14
Condition
renal support
NCT02715466_exc_T15
Mood
Requirement for
NCT02715466_exc_T16
Drug
heparin
NCT02715466_exc_T17
Condition
chronic coagulation disease
NCT02715466_exc_T18
Drug
anticoagulation medication
NCT02715466_exc_T19
Measurement
partial thromboplastin time
NCT02715466_exc_T20
Value
> 60 sec
NCT02715466_exc_T21
Scope
chronic coagulation disease / anticoagulation medication
NCT02715466_exc_T22
Condition
Acutely burned